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Preamble
Against the background of the sub-
sisting high childhood mortality
indices in Nigeria, vis-a-vis the
global efforts in the last 10 years to
stem the tide (as articulated in the
Millennium Development Goals),
there has been a corresponding need
to address the common causes of
deaths in under- fives. In Nigeria,
as is the case in many countries in
DOI:http://dx.doi.org/10.4314/njp.v42i4.1
sub-Saharan Africa, pneumonia
remains a common cause of under
-five mortality, accounting for
17% of deaths in this age-group.
Indeed, it has been estimated that
globally,
a child dies from pneumonia
every 20 seconds. With these in
mind, and indeed the laudable
goal of a 66% reduction of the
national under-five deaths by the
year 2015, a prompt recognition
and management of pneumonia
(in this vulnerable paediatric
population) has become impera-
tive. This was the logic that in-
formed the current initiative of the
Paediatric Association of Nigeria,
aimed at formulating diagnostic,
treatment and control policies with
respect to paediatric community
acquired pneumonia (CAP). This
document is targeted primarily at
health care providers working in
Nigeria in centres with limited
facilities as well as those working
in tertiary hospitals.
facility.
b. Duration of Pneumonia: Pneumonia can be classi-
fied as "acute" (less than two weeks duration) and
"chronic". Chronic pneumonias tend to be either
mycobacterial or fungal. A microbiological classifi-
cation involves knowledge of the aetiological
agents.
c. Anatomical area(s) of involvement: Usually rec-
ognized based on chest radiographic parameters:
d. Lobar pneumonia: characterized by the presence
of a smooth, dense homogenous opacity of a single
lobe, or a segment of a lobe, of a lung. The aetio-
logical agent is often Streptococcus pneumoniae.
Multilobar pneumonia involves more than one lobe,
often causing a more severe illness.
e. Bronchopneumonia: there are patchy changes in
the lung around the bronchi or bronchioles.
f. Interstitial pneumonia: this involves the areas in
between the alveoli. It is more likely to be caused
by viruses or by atypical bacteria
g. Microbiologial classification: This is based on the
organism isolated/identified. This is exemplified by
viral, bacterial, fungal, mycoplasmal and
chlamydial pneumonia.
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Definition
Pneumonia is the inflammation of lung parenchyma due
to pathogenic micro-organisms such as bacteria, viruses
and fungi. Clinically, it is also defined as a condition
typically associated with fever, respiratory symptoms,
and evidence of parenchymal involvement, either by
physical examination or the presence of infiltrates on
chest radiograph. In order to facilitate early recognition,
prompt treatment and referral of children with pneumo-
nia, the World Health Organization (WHO) definition of
pneumonia relies on simple clinical signs, such as
tachypnoea and lower chest in-drawing (Table 1). Ac-
cording to this definition, severity classification of pneu-
monia in under-fives is non-severe and severe (Table 1).
Classification of pneumonia
Pneumonia can be classified using several parameters:
a. Source of infection: Community-acquired pneumo-
nia (CAP) and hospital acquired infection
(nosocomial) pneumonia. CAP is defined as pneu-
monia in a previously healthy child who acquired
the infection outside a health facility or develops the
illness within 48 hours of admission into a health
Epidemiology
Pneumonia is the leading cause of death in children un-
der five years around the world, accounting for ~ 20% of
all under-five mortality globally. Indeed, more than 155
million new episodes of clinical pneumonia occur in
children under 5 years of age annually with about 10%
of these being of sufficient severity to be life-threatening
requiring hospitalization. In 2011, for example, an esti-
mated 1.3 million children under five years died from
pneumonia. Nigeria ranked fifth among the countries
with the highest absolute number of new cases of clini-
cal pneumonia in 2008 with an estimated 6.1 million
new cases.   By 2010, the estimated number of under-
five children dying from pneumonia in Nigeria was
more than 120,000, a disease burden that constitutes the
highest in Africa. The burden of disease is mainly in the
younger age groups. Furthermore, while 81% of deaths
from pneumonia happen in children younger than 2
years, disease incidence has been shown to fall less rap-
idly with age than does mortality from the disease. Also,
the global pneumonia incidence shows a higher preva-
lence among boys than girls with the largest differences
recorded in South Asia regions. Indeed the recent series
by Abdulkarim in Ilorin reported a male to female ratio
of 1.5:1.
Aetiological Agents
The aetiological agents of CAP could be divided into














Respiratory syncytial virus (RSV)
Influenza A & B virus
Parainfluenza







Globally, the common pathogens of CAP and the corre-
sponding paediatric population are:
General population of children
The two commonest bacteria are Streptococcus pneumo-
niae (30–50% of pneumonia cases) and H. influenzae
type b (Hib; 10-30% of cases), and the main viral cause
is RSV, but estimates of their relative importance vary
in different settings.
HIV-infected children
Pneumocystis jiroveci and Mycobacterium tuberculosis
areimportant causes of pneumonia, though bacterial
causes remain the major cause of pneumonia mortality.
Severely malnourished children
Klebsiella pneumoniae, S. aureus, S. pneumoniae, E.
coli, and H. influenzaeare the major aetiological agents
with very few data on the role of respiratory viruses and
M.tuberculosis.
Neonates
The organisms responsible for pneumonia in this age
group are essentially similar to those causing neonatal
sepsis and include gram-negative enteric organisms such
as E.. coli, Klebsiella spp, and gram-positive organisms,
mainly S. pneumoniae, S. aureus and group B Strepto-
coccus.
School-aged children
Mycoplasma pneumoniae is an important cause of pneu-
monia in school-aged children.
However, in Nigeria pathogens causing CAP in the un-
der-fives are as shown in the table below:
Table 1: Aetiological agents of childhood pneumonia in
Nigeria
Results of aetiology of pneumonia studies in Nigeria are at
variance with the global trend due to a) high pre-consultation
antibiotic use; b) use of human blood to prepare blood agar;
and c) lack of current method to distinguish coagulase




Staphylococcus aureus (23.9%), Klebsiellaspp
(17.4%), coliforms and coagulase negative
Staphylococcus(15.2%) each; micrococcus and
non-haemolytic Streptococcus(6.5%) each
Falade et al 2009 S. pneumoniae (9), Hib (2), and others- Klebsiel-
laspp (14 cases), Salmonella spp (11), Pseudo-
monas. aeruginosa (6 ), Enterococcus. faecalis
(2 ), E. coli (2), and possible S. aureus (44) but
only 1 of the 44 isolates was confirmed
Johnson et
al2008
Bacteria:S. aureus (37.3%), Klebsiella spp.
(15.3%) and S. pneumoniae (5.1%). 92 viruses:
RSV (30.4%), PIV-3 (19.5%) Flu-A (17.3%)
Tagbo et al2005 S.pneumoniae (3), S. aureus (2), coliforms (2),




Risk factors for CAP include the following:
Table 2: Risk Categories of Community Acquired Pneumonia
(modified from Rudan et al Bull WHO 2008)
Pathophysiology and Pathogenesis of Pneumonia
The respiratory tract is replete with both specific and
non-specific protective mechanisms which act in concert
to keep the airways and alveoli free of both particulate
materials and microbes.
The non-specific defense mechanisms include the nasal
hair and nasal turbinates, the vocal cord, glottis, muco-
ciliary clearance and the cough reflex. Others include
humidification, neutrophils, resident alveolar macro-
phages, airway secretions including lysozymes, iron
binding proteins, complements and surfactant.
The specific defense system involves the coordinated
activities of B and T lymphocytes resulting in activation
of cytotoxic T cells and specific antibodies
Microbes are introduced to the airway via inhalational or
haematogenous route. When microbes evade the non-
specific defense system they provoke an inflammatory
response leading to exudates of plasma, neutrophils,
lymphocytes, macrophages and inflammatory debris.
The inflammatory debris narrows the airway and in-
creases airway resistance. The debris also causes partial
or total occlusion of the smaller airways with resultant
atelectasis and hyperinflation of some alveoli leading to
increased work of breathing and wheezing. Furthermore,
the increased alveolar diffusion barrier causes signifi-
cant ventilation-perfusion mismatch and intrapulmonary
shunt.
These pathophysiological events are responsible for (1)
tachypnoea (2) increased work of breathing (3) crepita-
tions (4) reduced air entry (5) dull percussion note (6)
wheeze/rhonchi and (7) fever
Seeding of bacteria to the blood and other organs could
also occur causing organ-specific manifestations,(such
as meningitis, septic arthritis, acute ostemyelitis), while
the inevitable increase in pulmonary vascular resistance
coupled with increased myocardial oxygen requirement
may cause heart failure.
Clinical Features
The main objective of the initial clinical assessment is to

















































findings are suggestive of CAP.
Clinical Assessment
1. Relevant history questions:
 Host-related factors: Age, immunization status, lack
of exclusive breastfeeding, low birth weight, severe
malnutrition
 Environmental Factors: household air pollution e.g.
firewood burning, passive tobacco smoking , season
of the year, overcrowding and poor ventilation
 Co-morbidities: heart disease, sickle cell disease,
HIV infection, gastro-esophageal reflux disease
2. An initial physical examination should be per-
formed for signs of respiratory illness and for fever.
These signs include tachypnoea, evidence of in-
creased work of breathing, cyanosis, auscultatory
signs such as decreased breath sounds, crepitations
and bronchial breath sounds. Other features to be
looked for include evidence of other organ involve-
ment such as heart failure (tachycardia, tender hepa-
tomegaly), acute osteomyelitis, septic arthritis and
meningitis
The following points should be noted, however:
1. Respiratory rates are best determined over a full 60-
second period and inconsistencies require repeated
observations. This is required in view of the effects
of the peculiar behavioral and physiologic factors in
children.
2. No single clinical finding is sufficient in determin-
ing the presence or absence of pneumonia; combi-
nations of clinical findings are more useful.
3. The best individual examination measures in chil-
dren less than 5 years are:nasal flaring (age < 12
months); oxygen saturation 90% or less in room air;
tachypnoea; and retractions. The absence of tachyp-
noea alone or of all other signs of respiratory illness
is highly suggestive of the absence of pneumonia.
4. Among children less than 5 years, especially in neo-
nates and those with severe malnutrition pneumonia
may be present without signs of respiratory illness.
Table 3: Respiratory Rate Cut-offs for Children According to
Age Groups
Classification of severity of pneumonia
Children with pneumonia usually present with cough
and/ or difficult breathing, fast breathing and fever.
These children may either have severe or non-severe
pneumonia, as defined below. This classification forms
the basis of subsequent management:





Less than 2 months 40 to 60 ≥60
2 up to 12 months 25 to 40 ≥50
1 up to5 years 20 to 30 ≥40
≥ 5 years 15 to 25 ≥30
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a.   Pneumonia (non-severe)
 Mild chest indrawing: (i.e. lower chest wall goes in
when the child breathes in)
 chest auscultation signs: decreased breath sounds,
bronchial breath sounds, crackles or crepitations
b.   Severe pneumonia
These children will have, in addition to the features of
non-severe pneumonia, at least one or more of the fol-
lowing:
 Central cyanosis, or oxygen saturation 90% or less
on pulse oximetry in room air
 Severe respiratory distress (e.g. grunting, very se-
vere chest indrawing)
 chest auscultatory signs: decreased/absent breath
sounds or vocal resonance as in pleural effusion,
pleural rub
 Signs of pneumonia with a general danger sign:
Inability to breastfeed or drink, lethargy or uncon-
scious, convulsions.
 Presence of complications or co-morbidities: e.g.
congestive heart failure, severe malnutrition and
sickle cell disease
Clinical chest examination is useful in providing ana-
tomical diagnosis (Table 4):
Table 4: Chest Signs of Lobar and Bronchopneumonia
Diagnostic Evaluation
Management of CAP can be in a community or hospital
settings. Community setting includes: the home, health
centres, community pharmacy shops/stores; as against
hospital setting, i.e. emergency departments, out-patient
and in-patient departments.. Emphasis on community
setting is on treatment of symptoms and prevention of
progression to severe cases of pneumonia in order to
avoid hospitalization.
For a child with suspected CAP in the community, there
are no indicators for any general investigations. Investi-
gation of any sort is not necessary and where this has
been done, it has not contributed to outcome of manage-
ment. We recommend instruction on respiratory rate
count for mothers, pharmacy assistants and community
health workers as part of capacity building for recogni-
tion of varying severity of the disease and appropriate
referral option. Also recommended is the knowledge of
the haemoglobin genotype of the child.
At hospital setting, aims of management include aetio-
logical diagnosis, anatomical/pathological diagnosis and
determination/correction of effects of the CAP on the
child.
Supportive Investigations
 Anthropometry – weight, height, mid upper arm
circumference
 Bedside determination of respiratory rate and pulse
rate
 Pulse oximetry for oxygen saturation: Helpful in
monitoring response to therapy and detection of
cyanosis. Acceptable cut-off value for discontinuing
oxygen therapy is is SPO2 90% or more.
 Acute phase reactants (APR), C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), pro-
calcitonin (PCT). While these non-specific inflam-
matory markers may be of clinical benefit, their
usefulness in differentiating the cause or indeed the
severity of the CAP is doubtful.
Diagnostic Imaging
Diagnosis of CAP is commonly achieved by carefully
considering the symptoms and signs, and in the majority
of cases, further investigations are uncalled for, espe-
cially in resource-poor countries.
Plain chest radiograph is the commonest ancillary inves-
tigation for confirmation of CAP. Its main value is the
identification of opacities in the chest radiograph.
Indications for chest radiograph in CAP include:
a. Presence of significant chest retractions
b. Failure to respond to initial course of antibiotic ther-
apy at 48 hours
c. Suspected CAP with complications, e.g. pleural
effusion, pneumothorax
d. Progressive symptoms despite antibiotic therapy
In general CAP requiring hospitalization is an indication
for requesting a chest radiograph. There is controversy
regarding the timing and the specific views of the chest
radiograph required. The majority of clinicians favour
chest radiograph for severe pneumonia at presentation,
while others favour chest radiograph as a pre-discharge
recommendation. Follow-up chest radiographs are un-
necessary in children who recover uneventfully from
CAP. Commonly, anteroposterior (AP) view is all that is
required. In the Nigeria situation, simultaneous AP and
lateral views are preferred in order to assess additionally
the hilum, paratracheal and paravertebral structures.
Where massive effusion is suspected, lateral views
should also be obtained following a substantial drainage
of the effusion.
Possible chest radiograph findings indicative of CAP
include: lobar infiltrates, interstitial infiltrates (bacterial,
Signs Lobar pneumonia Broncho-
pneumonia
Chest deformity None None
Chest movement Diminished or absent Normal
Mediastinal shift None None
Vocal fremitus Increased Normal
Percussion  note Dull Resonant
Breath sound Bronchial or vesicular Vesicular
Added sound Crepitations (crackles) Crepitations
(crackles)
Vocal resonance Increased Normal
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viral, atypical pneumonia), lobar consolidation, atelecta-
sis, nodular infiltration, hilar adenopathy, pneumato-
coeles, etc.
However, the ‘gold standard’ for the diagnosis of pneu-
monia is chest radiography. Nevertheless, some of the
limitations of chest radiography include:
1. Interpretation of the chest radiographs in pneumonia
varies  as some studies classify only cases with al-
veolar consolidation as pneumonia, others include
the presence of any pulmonary parenchymal infil-
trates
2. Poor agreement between radiologists on the pres-
ence or absence of infiltrates in paediatric chest
radiographs even when standard reporting formats
are used.
3. Chest radiographs predict the post-mortem diagno-
sis of pneumonia in severely malnourished children
with 100% specificity but only 50% sensitivity.
4. Facility for chest radiography is not available in
most health facilities in developing countries
There is no sufficient evidence to recommend the rou-
tine use of ultrasound and computerized tomography
scan in CAP.
Isolation of Microbiologic Agents
This is a desirable investigation in children with CAP in
order to avoid antibiotics misuse and development of
bacterial resistance. Available methods include blood
culture, pleural fluid culture, nasopharyngeal culture,
sputum (induced using 5% normal saline) culture, etc.
However, the gold standard for sample recovery is lung
puncture aspirate from infected region of the lung. Em-
phasis should be on the less invasive sampling methods
Although new molecular diagnostic tests are available,
e.g., polymerase chain reaction (PCR), their usefulness
in our hospital setting is limited.
Recommendations for Management of Community
Acquired Pneumonia
Introduction
Results of aetiological studies of CAP in Nigeria, as
well as its complications are essential to formulate its
management. It is paramount to consider the manage-
ment as first/alternative and second lines, which will fit
into management at primary, secondary and tertiary lev-
els.
A stepwise approach to management is preferred: In
children with a history of fever, cough, and/or difficult
breathing:
Step 1: Count the respiratory rate for one full minute
when the child is awake and calm, or asleep. If the
breathing is fast, consider pneumonia.
Step 2: Look for evidence of increased work of breath-
ing (difficult breathing): in-drawing of the lower chest
wall when the child breathes in and nasal flaring
Step 3: Check for cyanosis (bluish discolouration) by
looking at the tongue and buccal mucosa. Document the
oxygen saturation using a pulse oximeter.
Step 4: Palpate for the position of the trachea
Step 5: Percuss the chest for dullness, or hyper-
resonance
Step 6: Auscultate for bronchial breath sounds, crepita-
tions or rhonchi.
Step 7: Look for complications such as heart failure
(tachycardia, tender hepatomegaly), pleural effusion
(stony dull percussion note, reduced/absent breath sound
over the region of either or both chest regions), pneu-
mothorax (hyper-resonance and reduced/absent breath
sound over the upper and lateral region of the involved
lung field).
Step 8: Look for signs of other organ involvement. Ask/
determine if convulsion, lethargy, inability to drink or
feed or not responding to calls is present. Presence of
these features or any of the complications listed above
indicates severe pneumonia.
Step 9: Classify the severity of pneumonia (using WHO
classification; see above)
Step 10: Decide on who needs hospitalization. Criteria
for management in the hospital are:
 Age less than 2 months
 Severe pneumonia
 Presence of complications or co-morbidities
 SpO2 90% or less in room air.
Step 11: Decide on relevant investigations:
 Chest radiography is NOT required in children with
pneumonia to be managed as outpatient
 Do chest radiography in children with pneumonia
needing hospitalization, more so in those children
suspected of having complications such as parap-
neumonic effusion (pleural effusion, empyema) or
pneumothorax
 Routine full blood count is NOT required for chil-
dren suspected of having pneumonia to be managed
in the outpatient
 A full blood count should be obtained for all chil-
dren with severe pneumonia or sick enough to be
hospitalized.
 Because malaria is a common co-morbidity in this
environment, screen for malaria parasite
 Blood culture should be obtained in sick children
requiring hospitalization
Serum electrolytes, urea and creatinine, and random







First line Alternatives* First line Alternatives*
<2 months Admit and treat as neonatal sepsis








nent 90mg/kg/dayin 2 di-
vided doses) OR oralcefpo-
doxime (10mg/kg/day in 2
divided doses) OR oral
cefuroxime (20-30mg/kg/
day in 2 divided doses) for






daily) for at least 5
days
IV ceftriaxone (50-100mg/kg/day every
12-24hours), OR
IV cefotaxime (100-200mg/kg/day in 4
divided doses), OR
IV/IM genticin (5 -7.5mg/kg once daily)
AND IV cloxacillin (100-200mg/kg in 4
divided doses)OR
IV cefuroxime (150mg/kg/day in 3 di-
vided doses)AND IV/IM genticin (5-











nent 90mg/kg/dayin 2 di-
vided doses) OR oralcefpo-
doxime (10mg/kg/day in 2
divided doses) OR oral
cefuroxime (20-30mg/kg/
day in 2 divided doses) for











IV ceftriaxone (50-100mg/kg/day every
12-24hours), OR
IV cefotaxime (100-200mg/kg/day in 4
divided doses) OR
IV cefuroxime (150mg/kg/day in 3 di-
vided doses)AND IV/IM genticin (5-
7.5mg/kg once daily)
PLUShigh dose co-trimoxazole (20mg/
kg/day of trimethoprim in 4 divided












nent 90mg/kg/dayin 2 di-
vided doses) OR oralcefpo-
doxime (10mg/kg/day in 2
divided doses) OR oral
cefuroxime (20-30mg/kg/
day in 2 divided doses) for









in 4 divided doses))
for at least 5 days
IV ceftriaxone (50-100mg/kg/day every
12-24hours), OR
IV cefotaxime (100-200mg/kg/day in 4
divided doses) OR
IV cefuroxime (150mg/kg/day in 3 di-
vided doses) AND IV/IM genticin (5-
7.5mg/kg once daily) for at least 5 days
PLUS oral azithromycin ( 10 mg /kg)
daily dose for 3 days
Notes:
Step down to appropriate oral antibiotics when improvement is sustained. For instance, cefpodoxime after ceftriaxone; Target
pathogens in outpatients’ treatment are S. pneumoniae and Hib; whereas in cases on admission, these as well as S. aureus and other
bacilli are included; Maximum dose of gentamicin should not exceed 120mg; Chloramphenicol is not included in the antibiotic
protocol because of its toxicity in the face of effective alternative antibiotics;
*Alternatives: Consider alternatives when first line drugs are not available or applicable or child has not responded to the first line
drugs
fluid. Ensure it contains at least 5% glucose (e.g.
5% dextrose in 0.9% saline or ringer’s lactate with
added glucose)
 For high grade fever (temperature ≥39oC), give
paracetamol 10-15mg/kg 4-6 hourly, and ibuprofen
if required.
 If widespread rhonchi is present (high-pitch con-
tinuous sound during expiration only or during both
phases of respiration) give first dose of short acting
bronchodilator such as salbutamol or albuterol and
re-assess
 Nursing care should be provided at least every 3
hours: check vital signs including oxygen saturation
 The doctor should review the child at least twice
daily
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Step 12: Give systemic antibiotics to all children with pneumonia
Other Supportive Measures
 Clear the airway using gentle suction as needed,
always mouth before nose
 Give supplemental oxygen if oxygen saturation is
90% or less, in room air or signs of severe respira-
tory distress are present. If pulse oximetry is not
available give oxygen if signs of respiratory distress
and or cyanosis are present.
 Give oxygen via nasal prongs or nasal catheters: 0.5
-1L/min for children 0-2months, 2-3L/min for chil-
dren 3months to 5 years; maximum of 4L/min for
older children)
 Allow small frequent feeds/fluids if tolerated; feed-
ing may also be done using appropriate size na-
sogastric tube
 If feeds are not tolerated give intravenous isotonic
When to Consider Referring a Child with Pneumonia to
a Tertiary Centre/Getting a Specialist’s Review
 If child’s clinical state does not improve after 48
hours or worsens within this period
 When the child requires mechanical ventilation at
presentation
 If oxygen saturation is persistently <90% despite
supplemental oxygen
 If blood pressure remains low If the child has al-
tered mental status
When to consider transfers to a Critical Care Unit
 When the child requires mechanical ventilation
 If blood pressure remains low or child requires ino-
tropic agent(s) to maintain normal blood pressure
 If the child has altered mental status
 If oxygen saturation is persistently <90% despite
supplemental oxygen
 Presence of other organ failure
When to Consider Discharge
 When clinical features such as fast breathing, respi-
ratory distress and fever have resolved for at least
24 hours
 Child is feeding by mouth and tolerates oral medi-
cations and
 Caregiver is comfortable about discharge from hos-
pital and capable of administering oral medication
(s) if any
At Discharge
 Plan to review the child two days after discharge
 Review immunization record and make plans to get
the child fully immunized if vaccines have been
missed. In addition, children under 2 years should
get recommended doses of pneumococcal conjugate
vaccines  (PCV) or H. influenzae Type b conjugate
vaccines(Hib vaccine) if not already immunized
 Instruct caregiver to bring child to the hospital when
child with cough and catarrh develops fast breathing
 Instruct caregiver to increase frequency of feeding
for the next 2 weeks after treatment for pneumonia.
Children with moderate to severe malnutrition
should receive treatment advice according to stan-
dard guidelines
Drugs to Avoid in the Management of Pneumonia
Cough syrups containing antihistamines or opioids
such as codeine, hydrocodeine, because they add little to
the management of pneumonia and may be toxic in
some children
Counselling/Health Education For CAP
Health education and guidance play important roles in
the management of children with CAP. Counselling
should be ongoing from admission to discharge with
family regularly updated on progress of management.
Information on what the caregiver should observe in the
child and report to the health facility should be commu-
nicated.
The education should include:
1. The fact that CAP is caused by micro-organisms.
2. Environmental factors that predispose to CAP and
CAP-related deaths such as indoor air pollution
including passive parental smoking, overcrowding,
poor ventilation, poor personal and environmental
hygiene. Good hand washing practices should be
emphasized.
3. Education about the presenting features with em-
phasis on the need for early recognition of fast
breathing.
4. Immunization against the childhood diseases. Vac-
cines that protect against pneumonia such as Pneu-
mococcal conjugate vaccine (PCV), Haemophilus
influenzae type B vaccine (Hib), pertussis, and mea-
sles vaccines should be communicated.
5. The importance of Exclusive breastfeeding in the
first 6 months of life and adequate nutrition should
be explained to the caregiver.
6. Opportunities should be given for the caregivers to
express his/her fears, so that cultural and religious
beliefs that are detrimental to achieving optimal
health and development of the child should be dis-
cussed.
7. The need to avoid self-medications including the
use of cough mixtures
Prevention
There are proven strategies for the prevention of com-
munity acquired pneumonia in children. These include:
Specific Vaccines
Conjugate vaccine for S. pneumoniae
Conjugate vaccine for H. influenzae type b
Influenza vaccine
Other vaccines
Measles containing vaccine (including booster doses)
BCG vaccine
Pertussis vaccine (now in pentavalent vaccine used na-
tionwide; including booster doses)
Measures to reduce risk factors
Improved housing:  improved ventilation, reduce over-
crowding and indoor air pollution
Improved nutrition
Exclusive breastfeeding for the first 6 months
Micronutrients supplementation, including vitamin A
and zinc




Paucity or absence of recent data on various aspects of
childhood community acquired pneumonia in Nigeria
makes it imperative for research strategies directed at
filling the knowledge gaps in:
1. Viral contribution to aetiology of CAP
2. Bacterial super-imposition following an initial viral
infection
3. Seasonal variations in the contribution of various
organisms to childhood community acquired pneu-
monia
4. Contribution of Mycoplasma pneumoniae to child-
hood community acquired pneumonia
5. Severity grading of childhood community acquired
pneumonia
6. Antibiotic resistance/sensitivity pattern of common
organisms causing community acquired pneumonia
7. Appropriate and relevant clinical scoring tool for
pneumonia
8. Usefulness of procalcitonin and C-reactive protein
in the diagnosis of CAP
9. Surveillance study on the prevalent pneumococcal
serotypes  in CAP
10. Surveillance study on the prevalence and the role of
non-typeable Haemophilus influenzae in CAP
Appendices
Appendix I: Lung Sound Nomenclature
NB: Wheezes and Rhonchi may be heard in severe Pneumonia
Appendix II: Methods of Oxygen Delivery
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